癌基因驱动的局部先进的不可切除的非小细胞肺癌的管理
Jerold Loh1, Jia Li Low1, Manavi Sachdeva1
1Department of Haematology-Oncology, National University Cancer Institute, Singapore (NCIS), National University Health System, Singapore, Singapore.
局部晚期非小细胞肺癌 (LA-NSCLC) 的标准治疗可能在具有特定瘤基因阳性瘤的患者中效果较差. 包含有针对性的治疗方法的个性化治疗策略对于改善生存结果至关重要.
科学领域:
- 在瘤学瘤学.
- 医学科学 医学科学 医学科学
- 癌症研究 癌症研究
背景情况:
- 局部晚期非小细胞肺癌 (LA-NSCLC) 的标准治疗包括化学辐射,然后是杜尔瓦卢马布.
- 有证据表明,在某些瘤基因阳性LA-NSCLC亚组中,目前的治疗疗法的疗效降低了.
- 瘤微环境因素可能会影响不同的治疗反应.
研究的目的:
- 审查在癌基因驱动的LA-NSCLC中标准治疗的结果.
- 探索瘤基因驱动子组和瘤微环境对治疗反应的影响.
- 评估向治疗在LA-NSCLC治疗中的作用.
主要方法:
- 在基因驱动的LA-NSCLC中对标准护理结果的文献综述.
- 对瘤基因子组及其相关瘤微环境的分析.
- 对LA-NSCLC针对性治疗的当前研究的综述.
主要成果:
- 在不同瘤基因阳性LA-NSCLC亚组中,标准护理的疗效有很大差异.
- 瘤微环境特征与不同的治疗反应有关.
- 针对性疗法在改善特定患者群体的治疗结果方面表现有前途.
结论:
- 对LA-NSCLC的治疗策略必须根据特定的瘤基因阳性亚组进行个性化.
- 需要进一步的研究和优化的临床试验设计,以有效地纳入向疗法.
- 管理治疗毒性对于实现LA-NSCLC针对性治疗的全部潜力至关重要.
更多相关视频
04:04Endobronchial Ultrasound-guided Intratumoral Injection of Cisplatin for the Treatment of Isolated Mediastinal Recurrence of Lung Cancer
Published on: February 12, 2017
09:38Establishment and Characterization of Three Afatinib-resistant Lung Adenocarcinoma PC-9 Cell Lines Developed with Increasing Doses of Afatinib
Published on: June 26, 2019
相关概念视频
Treatment Resistant Cancers
Targeted Cancer Therapies
There are several types of targeted therapies against...
Combination Therapies and Personalized Medicine
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
Cancer Therapies
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
Tumor Immunotherapy
